Pain Therapeutics, Inc. Stock Nasdaq
Equities
US69562K5065
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 300M | Capitalization | 849M |
---|---|---|---|---|---|
Net income 2024 * | -92M | Net income 2025 * | 120M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.83 x |
P/E ratio 2024 * |
-9.77
x | P/E ratio 2025 * |
11.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.83% |
Managers | Title | Age | Since |
---|---|---|---|
Remi Barbier
CEO | Chief Executive Officer | 64 | 98-04-30 |
Eric Schoen
DFI | Director of Finance/CFO | 55 | 18-09-30 |
James Kupiec
CTO | Chief Tech/Sci/R&D Officer | - | 21-01-03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Remi Barbier
CEO | Chief Executive Officer | 64 | 98-04-30 |
Robert Gussin
BRD | Director/Board Member | 86 | 03-02-28 |
Patrick Scannon
BRD | Director/Board Member | 76 | 07-12-06 |
1st Jan change | Capi. | |
---|---|---|
-3.10% | 102B | |
+2.11% | 96.07B | |
-1.80% | 21.66B | |
-17.75% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-28.19% | 13.79B | |
+0.18% | 13.33B | |
+19.90% | 10.94B |